Arthneeti
VS

Vaidya Sane Ayurved Laboratories Ltd

Q2 FY27Healthcare Equipment & Supplies

Vaidya Sane Ayurved Laboratories Q2 Results 2026 (FY27) statement: Revenue & Margins

Q2 FY27 results statement: what the company reported on revenue, margins and capex.

Based on Vaidya Sane Ayurved Laboratories Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.

Price₹136
Market cap₹143 Cr
P/E15.9

The short version

Revenue from operations for the half year ended September 30, 2026, was INR 4,635.71 lakhs vs. EBITDA for the quarter ended September 30, 2026: INR 849 Lakhs.

From Vaidya Sane Ayurved Laboratories Ltd's Q2 FY27 earnings-call transcript · updated 7 Nov 2026.

How did Vaidya Sane Ayurved Laboratories' revenue grow in the September 2026 quarter?

  • Revenue from operations for the half year ended September 30, 2026, was INR 4,635.71 lakhs vs. INR 4,718.57 lakhs for the half year ended September 30, 2025, indicating a slight year-on-year decrease.
  • Segment revenue for Hospital Activity for the half year ended September 30, 2026, was INR 1,277.15 lakhs vs. INR 1,290.19 lakhs in the previous year same period.
  • Sale of Product Activity segment revenue was INR 3,087.95 lakhs for the half year ended September 30, 2026, vs. INR 3,117.59 lakhs for the prior year period.
  • The standalone Statement of Profit and Loss confirms total revenue from operations of INR 4,635.71 lakhs (H1 FY 2026) vs. INR 4,718.57 lakhs (H1 FY 2025).

What happened to Vaidya Sane Ayurved Laboratories' margins in Q2 FY27?

See what Vaidya Sane Ayurved Laboratories Ltd said on profitability & margins — free account, 30 seconds.

What capex is Vaidya Sane Ayurved Laboratories planning?

The presentation mentions the following capex, capacity expansion, or new projects: - Capital Work-in-Progress stood at INR 630.59 lakhs (Standalone) and INR 630.59 lakhs (Consolidated) as of September 30, 2026, indicating ongoing projects. - Intangible Assets under Development valued at INR 197.85 lakhs (Standalone) and INR 230.81 lakhs (Consolidated), reflecting investments in new capabilities or products. - Significant purchase of Property, Plant and Equipment and Intangible Assets amounting to INR 777.62 lakhs (Standalone) and INR 1,424.24 lakhs (Consolidated) during the half year ended September 30, 2026.

Top-ranked in Healthcare Equipment & Supplies

Ranked on what management guided this quarter

Guidance-ranked
1OSEL Devices
Rev 1Mar 3
2Avience Biomedicals
Rev 1Mar 3
3
Rev 2Mar 3
4
Rev 2Mar 3
5
Rev 3Mar 2
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Vaidya Sane Ayurved Laboratories raising money or cutting debt?

See what Vaidya Sane Ayurved Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.

How big is Vaidya Sane Ayurved Laboratories' order book?

The presentation states the following about orders: - The contents relate to financial performance (income, expenses, profit), regulatory filings (related party transactions, deviations), and audit remarks.

Continue your research

What Vaidya Sane's management said in earlier quarters

Earlier calls (2)

Others in Healthcare Equipment & Supplies this season

  • Vasa Denticity (Q2 FY27)

    Year-on-year revenue growth: Approximately 95.3% increase in revenue from Rs. Key results statement takeaways from Vasa Denticity Ltd's Q2 FY27 results statemen

  • Sahajanand Medi (Q2 FY27)

    Slight seasonality in revenue with H2 being marginally higher (~52%) than H1 (~48%). Key concall takeaways from Sahajanand Medical Technologies Ltd's Q2 FY27…

  • Molbio Diagnosti (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹259.0 Cr vs ₹580.3 Cr in Q2 FY26 (significant decrease due to rate contract negotiations). Key investor presentation takeaways

  • Poly Medicure (Q2 FY27)

    Q2 FY27 consolidated revenue from operations: Rs 580.5 Cr, up 30.8% YoY (Q2 FY26: Rs 443.9 Cr). Key investor presentation takeaways from Poly Medicure Ltd's Q2

Compare:vs Poly Medicurevs Molbio Diagnostivs Sahajanand Medi

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Vaidya Sane Ayurved Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Vaidya Sane Ayurved Laboratories Ltd Q2 FY27 results?

Revenue from operations for the half year ended September 30, 2026, was INR 4,635.71 lakhs vs. EBITDA for the quarter ended September 30, 2026: INR 849 Lakhs.

What is Vaidya Sane Ayurved Laboratories Ltd share price analysis?

Vaidya Sane Ayurved Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 15.9 with a market cap of ₹143 Cr. Investors should review the full earnings analysis for detailed insights.

Is Vaidya Sane Ayurved Laboratories Ltd planning capital expenditure?

The presentation mentions the following capex, capacity expansion, or new projects:.

Keep Vaidya Sane Ayurved Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.